- Display 15 Products per page
Published: May 11, 2017 | Price: $3,196.00 – $6,392.00
Virtual Reality and Augmented Reality (VR/AR) Market in Healthcare (U.S. Markets for Surgery; Medical Education and Training; Pain Management, Rehabilitation and Therapy) Virtual Reality and Augmented Reality (VR/AR) Market in Healthcare provides market analysis and examines applications for virtual reality (VR) and augmented reality (AR) in healthcare, including the following: • the Total US Market for VR/AR in Surgery (2012/2017/2022) • the Total US Market for VR/AR in Pain Management, Rehabilitation and Therapy (2012/2017/2022) • the Total US Market for...Published: April 1, 2005 | Price: $995.00 – $1,990.00
Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality. This briefing examines both corrent and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses...Published: September 27, 2012 | Price: $12,784.00
Kalorama's Medical Contrast Agents market research report and Molecular Imaging Report for global license in one bundled offering.Published: January 31, 2015 | Price: $1,995.00 – $3,990.00
The Market for IVD in Latin America The Market for IVD in Latin America is an essential resource for IVD companies seeking market information for developing countries with growing economies. Kalorama Information, and VA Consultadora y Asociados of Argentina have published detailed nation by nation market analysis of the IVD markets in LATAM and thier segment markets. Each country in Latin America is different in terms of their healthcare system, insurance services, laws and industry participants. For this reason, this...Published: November 1, 2005 | Price: $3,500.00 – $7,000.00
Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment of conditions and diseases affecting pediatrics and the healthy growth of children are vital to providing a solid foundation for healthy adults in the future....Published: January 1, 2014 | Price: $1,995.00 – $3,995.00
IVD in Singapore and Malaysia Regional opportunities are the focus of IVD manufacturers that seek marginal growth. Southeast Asia represents a unique market for healthcare providers and their various business suppliers, including the in vitro diagnostics (IVD) industry. Kalorama details in this report two countries expected to provide business for IVD manufacturers: Singapore and Malaysia. IVD in Singapore and Malaysia contains the following information: Healthcare Statistics for Singapore and Malaysia Significant Hospitals in both countries The Clinical Lab Market in...Published: April 1, 2005 | Price: $1,995.00 – $3,990.00
This timely overview of direct to consumer (DTC) pharmaceutical marketing examines the numerous issues surrounding DTC practices and markets, using industry and consumer publications as well as interviews with industry experts. The topics examined include: DTC marketing spending by product, DTC marketing spending by company DTC marketing spending by media channel The ROI debate on the cost-effectiveness of DTC marketing expenditures Arguments for and against DTC marketing by its proponents and critics DTC marketing regulations in the U.S. and selected...Published: October 28, 2019 | Price: $4,000.00 – $8,000.00
The Global Market for Medical Devices, 10th edition, provides a comprehensive view of the medical device market and opportunity for medical device manufacturers, competitors, and investors. The report examines the companies in the market, the types of devices sold across the global market, and the country markets they are sold in. As part of its coverage, this report contains market sizing and forecasts for the world medical device market and the medical device markets of 50 countries, providing the following...Published: March 1, 2009 | Price: $995.00 – $5,990.00
Wound care is a constantly changing market. The trend toward cost-effective skin ulcer treatment remains embedded in management programs that emphasize prevention and early intervention. New wound care products and devices are entering the market with lightening speed, all striving for the best clinical outcomes. Kalorama's Wound Care Markets, 4th Edition, Vol. I: Skin Ulcers. represents the fourth time that Kalorama has rexamined this aspect of the wound care market, and the study analyzes the market using the following product...Published: January 9, 2023 | Price: $5,000.00 – $10,000.00
This report analyzes trends in global demand for in vitro diagnostic (IVD) products used in physicians’ office laboratories. Specific products consist of reagents, test kits, standards and controls, and instruments and systems based on immunoassay, clinical chemistry, hematology, molecular, microbiology, and coagulation technologies. Physicians’ office laboratories are defined as point-of-care (POC) testing sites within traditional practices or urgent care centers staffed by one or more physicians. Most of these laboratories implement IVD procedures through one or more portable desktop instruments...Published: July 1, 2004 | Price: $3,500.00 – $7,000.00
After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to streamline operations and cut costs as they strive to continue generating above-average shareholder returns. Outsourcing has become an integral, ongoing element of pharmaceutical companies’ business...Published: September 24, 2020 | Price: $5,500.00 – $11,000.00
Laboratory developed tests (LDTs) are not a new or recent phenomenon but due to the incredible need for testing of SARS-CoV-2, there has been a flood of new tests and the regulatory guidance has changed dramatically. Historically, these tests were called “home-brew tests” or “in-house tests.” Also, historically, these tests were low-volume, simple and well characterized tests for low-risk diagnostic applications. Today, high-risk, complex tests have been developed as LDTs, and are being used to provide clinical results to physicians...Published: October 9, 2014 | Price: $995.00 – $7,990.00
Stem cells are anticipated to demonstrate considerable efficacy in clinical treatment and revenues to manufacturers with suitable products. Kalorama Information’s Stem Cell Therapeutics Markets is a complete analysis of stem cell drugs now and in development. The report estimates the opportunity by for novel technologies through an assessment of current products, pipeline, cost trends and regulation. Bottom-up and Top-Down analysis was used to determine market size and market forecasts. Over the next several years, as researchers introduce a growing variety...Published: May 13, 2025 | Price: $8,400.00 – $12,000.00
Now in its twelfth edition — Worldwide Market for Point-of-Care (POC) Diagnostic Tests analyzes the POC market from a global perspective with a five-year forecast. Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 12th Edition provides a comprehensive analysis of the global POC diagnostics market, with forecasts extending through 2029. While traditional lab-based analyzers remain central to the in vitro diagnostics (IVD) industry, the POC segment has emerged as a dynamic growth area, driven by the demand for rapid, accessible testing across diverse healthcare...Published: November 1, 2005 | Price: $2,500.00 – $5,000.00
Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% per year) to generic competition, if—and it’s a big if—the regulatory hurdles for these generics can be overcome. Biogeneric is a new term combining biologic...